Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas

Expert Opinion on Biological Therapy
Maro OhanianSusan O'Brien

Abstract

The expression profile of the CD22 antigen and its role in B-cell function make it an important target in B-cell leukemias and lymphomas. Inotuzumab ozogamicin (IO), a humanized monoclonal antibody targeting CD22, is one of the most promising monoclonal antibodies for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). This article reviews the current literature of IO in adult leukemias and lymphomas. Single-agent IO has demonstrated activity in patients with relapsed B-cell ALL and non-Hodgkin lymphoma (NHL). It has also demonstrated favorable early results when combined with chemotherapy in older patients with ALL. There is potential for IO to be combined with other targeted therapies under development for these diseases; data are still early and further studies of IO are warranted. While the pivotal randomized study of IO for relapsed NHL versus physician's choice did not show a statistically significant advantage in response rate, the results of the pivotal study in ALL are not yet available.

References

Jan 1, 1997·Annual Review of Immunology·T F TedderJ H Kehrl
Dec 30, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John F DiJosephNitin K Damle
Oct 18, 2005·Advances in Immunology·Thomas F TedderKaren M Haas
Jan 7, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John F DiJosephNitin K Damle
Oct 13, 2006·Blood·Adele K FieldingUNKNOWN Eastern Cooperative Oncology Group
May 13, 2008·Nature Reviews. Cancer·Klaus Strebhardt, Axel Ullrich
Dec 23, 2008·Seminars in Hematology·Nicola Gökbuget, Dieter Hoelzer
Jan 27, 2010·Cancer·Stefan FaderlHagop M Kantarjian
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anjali AdvaniLuis Fayad
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Renato Bassan, Dieter Hoelzer
Feb 24, 2012·The Lancet Oncology·Dieter Hoelzer
May 9, 2013·Oncotarget·Jonathan FeldAmit K Verma
May 30, 2013·American Society of Clinical Oncology Educational Book·Mark R Litzow
Jul 12, 2013·Leukemia & Lymphoma·Craig A Portell, Anjali S Advani
Jul 2, 2014·European Journal of Haematology·Caroline Le Jeune, Xavier Thomas

❮ Previous
Next ❯

Citations

Jan 20, 2016·Expert Review of Hematology·Jenny DahlElias Jabbour
Apr 6, 2016·Expert Opinion on Biological Therapy·Serengulam V GovindanDavid M Goldenberg
May 22, 2016·Current Oncology Reports·Aharon RonsonJacob M Rowe
Sep 30, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Magali GuffroyNasir Khan

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.